期刊文献+

美罗华联合CHOP方案治疗侵袭性B细胞淋巴瘤疗效分析 被引量:1

原文传递
导出
摘要 目的观察美罗华(抗 CD20抗体利妥昔单抗,rituxin-mab)联合 CHOP(R-CHOP)方案治疗侵袭性 B 细胞淋巴瘤的临床疗效、使用方法和安全性。方法 45例均为病理检查证实 CD20阳性的 B 细胞非霍奇金淋巴瘤患者,分为美罗华组和对照组。美罗华组22例采用美罗华联合CHOP方案治疗;对照组23例单用 CHOP 方案治疗。美罗华组:13例为初治,9例为化疗后复发;
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第S1期84-85,共2页 Chinese Journal of Practical Internal Medicine
  • 引文网络
  • 相关文献

同被引文献19

  • 1林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量:49
  • 2Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 [ J]. Blood, 2006, 107( 1 ) : 265-276.
  • 3Morton LM, Wang SS, Cozen W, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes [ J]. Blood, 2008, 112 (13) : 5150-5160.
  • 4Capietto AH, Keirallah S, Gross E, et al. Emerging concepts for the treatment of hematological malignancies with therapeutic mono- clonal antibodies [J]. Curr Drug Targets, 2010, 11 (7) : 790- 800.
  • 5Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform Meta-analysis of the published literature for survival end- points [J]. Stat Mcd, 1998, 17(24): 2815-2834.
  • 6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximah compared with CHOP alone in elderly patients with dif- fuse large-B-cell lymphoma [J]. N Engl J Med, 2002, 346(4) : 235 -242.
  • 7Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of re- sponse duration after salvage therapy with a combination of ritux- imab, fludarabine, cyclophosphamide, and mitoxantrone (R- FCM) in patients with recurring and refractory follicular and man- tle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) [ J]. Blood, 2006, 108 ( 13 ) : 4003-4008.
  • 8Herold M, Pasold R, Sroek S. Results of a prospective randomised open label phase Ⅲ study comparing rituximab plus mitoxantrone, eblorambueile, prednisolone chemotberapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin' s lymphoma (NHL) and mantle-cell-lyrnphoma (MCL) [J]. ASH Annual Meeting Abstracts. 2004. 104( 11 ) : 584.
  • 9Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOF) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [ J ]. Blood, 2005, 106 ( 12 ) : 3725-3732.
  • 10Lenz G, Dreyling M, Hoster E, et ah Immanochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously un- treated mantle ceil lymphoma: Results of a prospective randonaized trial of the German Low Grade Lymphoma Study Group (GLSG) [J]. JClin Oncol, 2005, 23(9): 1984-1992.

引证文献1

二级引证文献9

;
使用帮助 返回顶部